<ref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="B158"><label>158</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramacciotti</surname><given-names>E</given-names></name><name><surname>Barile Agati</surname><given-names>L</given-names></name><name><surname>Calderaro</surname><given-names>D</given-names></name><name><surname>Aguiar</surname><given-names>VCR</given-names></name><name><surname>Spyropoulos</surname><given-names>AC</given-names></name><name><surname>De Oliveira</surname><given-names>CCC</given-names></name><etal/></person-group>. <article-title>Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial</article-title>. <source>Lancet</source>. (<year>2022</year>) <volume>399</volume>:<page-range>50&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02392-8</pub-id>, PMID: <?supplied-pmid 34921756?><pub-id pub-id-type="pmid">34921756</pub-id>
</mixed-citation></ref>